A Single-center, Open-Label, Drug Interaction Study to Determine the Effects of Apatinib on the Metabolism of CYP3A4/5 and CYP2C9 Probe Drugs in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Rivoceranib (Primary) ; Nifedipine; Warfarin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 06 Feb 2018 Status changed from not yet recruiting to recruiting.
- 16 Aug 2017 New trial record